Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $11.00

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been assigned an average recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $11.00.

Several research analysts have recently weighed in on the stock. StockNews.com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 8th. Cantor Fitzgerald upgraded shares of Aclaris Therapeutics to a “strong-buy” rating in a report on Thursday, January 30th. Leerink Partnrs upgraded shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 19th. Leerink Partners upgraded shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. Finally, BTIG Research upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective on the stock in a report on Tuesday, November 19th.

Insiders Place Their Bets

In other Aclaris Therapeutics news, Director Anand Mehra purchased 666,666 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were bought at an average cost of $2.25 per share, for a total transaction of $1,499,998.50. Following the completion of the purchase, the director now directly owns 710,030 shares of the company’s stock, valued at approximately $1,597,567.50. This trade represents a 1,537.37 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 6.40% of the company’s stock.

Institutional Trading of Aclaris Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. ExodusPoint Capital Management LP purchased a new stake in Aclaris Therapeutics during the fourth quarter worth about $26,000. Invesco Ltd. purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter worth approximately $28,000. Commonwealth Equity Services LLC purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter worth approximately $36,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter worth approximately $82,000. Finally, XTX Topco Ltd purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter worth approximately $111,000. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

Aclaris Therapeutics Trading Up 1.4 %

Shares of ACRS stock opened at $2.20 on Friday. The company’s 50-day moving average price is $2.72 and its 200-day moving average price is $2.08. The stock has a market cap of $157.15 million, a price-to-earnings ratio of -4.23 and a beta of 0.50. Aclaris Therapeutics has a twelve month low of $0.95 and a twelve month high of $5.17.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.